Atai reports its Q2 2022 results, announces a new $175 million loan facility and streamlines its operations.
INVESTOR PROFILE | Ionic Brands
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
52-Week
Range N/A
Range N/A
Current
Outstanding 108,436,715
Outstanding 108,436,715
Warrants
Options
Fully Diluted
Market Cap.
14,639,000
14,639,000
IONIC BRANDS (CSE: IONC) has a premium portfolio of cannabis concentrate consumer brands. Ionic Brands is one of the top selling concentrate company in Washington State.
Company Brief
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Highlights
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
In The News
Ionic Is Changing the Face of Cannabis and Creating a Social Revolution
It’s all in the URL: Ionic.social. “We believe our products are best when enjoyed in a social setting,” said co-founder Christian Struzan.
READ MORE
Marijuana Vaping Is The Most Explosive Growth Play In Marijuana Today
“Nobody smokes marijuana anymore, they vape it.” - New York Times That's not quite true. But it will be soon.
READ MORE
How To Invest In Marijuana Vaping
The marijuana vaporization products (or just "vape") market is set to explode in 2019.
READ MORE
Related Articles
MindMed Board of Directors Approves Reverse Share Split
Mind Medicine announces a reverse share split of its common shares at a 1-15 ratio. Exchange symbols will remain the same but new CUSIP numbers will be assigned by the appropriate regulators.
COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
Compass Pathways reports its Q2 2022 results. Preparing for its Phase 3 clinical trial for TRD. Net loss of $21.0 million. Cash (and equivalents) of $207.2 million.
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
Compass Pathways announces the launch of a Phase II clinical trial using psilocybin-based COMP360 as a treatment for anorexia nervosa.
Red Light Holland to Acquire Two Wellness Shops in the Netherlands: SmartShop Utrecht and SmartShop OSS
Red Light Holland acquires two of the Netherlands premier shops for psychedelic truffles and wellness products.
Pasithea Therapeutics Awarded a Drug Development Research Grant
Pasithea Therapeutics announces being awarded a research grant of AUD $1 million (US$694,000) for its psychedelics-based research for ALS disease.